Rein Therapeutics, Inc. Common Stock RNTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$5.84M+81.7% | -$31.97M-473% | -$5.58M+18.2% | -$6.82M-24.0% | -$5.5M+86.6% | ||
| —— | —— | —— | $1K— | $0— | ||
| $156K-39.3% | $257K-82.2% | $1.45M+465% | $256K-3.0% | $264K+98.5% | ||
| —— | $7.18M0.0% | $7.18M0.0% | $7.18M0.0% | $7.18M-22.4% | ||
| $2.29M— | —— | —— | $4.88M+1,950% | $238K+242% | ||
| $247K— | —— | -$34K+98.9% | -$3.16M-31,520% | -$10K-104% | ||
| -$103K— | —— | $219K— | —— | $125K+156% | ||
| $0— | —— | —— | —— | -$277K-200% | ||
| —— | -$178K0.0% | -$178K0.0% | -$178K0.0% | -$178K+54.2% | ||
| $623K— | —— | —— | —— | $0— | ||
| -$3.42M-6.3% | -$3.22M+9.2% | -$3.55M+44.7% | -$6.42M-3.9% | -$6.18M-28.3% | ||
| —— | —— | —— | —— | —— | ||
| $354K-75.6% | $1.45M— | —— | —— | $737K— | ||
| $4.65M+93.5% | $2.41M+26.6% | $1.9M-59.7% | $4.71M+538% | $738K+73,700% | ||
| $1.23M+248% | -$833K+50.2% | -$1.67M+1.9% | -$1.71M+68.6% | -$5.44M-13.0% | ||
| $623K— | —— | —— | —— | $0— | ||
| —— | $7.18M0.0% | $7.18M0.0% | $7.18M0.0% | $7.18M-22.4% | ||
| $247K— | —— | -$34K+98.9% | -$3.16M-31,520% | -$10K-104% | ||
| $0— | —— | —— | —— | -$277K-200% | ||
| $1M— | $0+100% | -$2.34M-248% | $1.58M+107% | $764K— | ||
| -$103K— | —— | $219K— | —— | $125K+156% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $4.3M— | —— | —— | —— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Rein Therapeutics, Inc. Common Stock generate?
- Rein Therapeutics, Inc. Common Stock (RNTX) generated -$16.6M in operating cash flow over the trailing twelve months.
- Where does Rein Therapeutics, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Rein Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.